Beclabuvir hydrochloride
Based on 6 publication(s) in Google Scholar
Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
For research use only. We do not sell to patients.
- CAS No.: 958002-36-3
- Formula: C36H46ClN5O5S
- Molecular Weight:696.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Beclabuvir hydrochloride
More- Cell Rep Med. 2026 Mar 9:102646. [Abstract]
- Genomics Proteomics Bioinformatics. 2025 May 10;23(1):qzaf008. [Abstract]
- Commun Biol. 2021 Jan 20;4(1):93. [Abstract]
- J Gastroenterol. 2019 May;54(5):449-458. [Abstract]
- Antiviral Res. 2026 Jun 22:252:106470. [Abstract]
- J Hum Genet. 2020 Jan;65(2):143-153. [Abstract]
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
|
RNA Polymerase |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 958002-36-3
-
Molecular Weight 696.30
-
Formula C36H46ClN5O5S
-
SMILES
O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(=O)(N(C)C)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3.Cl
-
Synonyms
BMS-791325 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]2026 Mar 9:102646. PMID: 41806841 -
Genomics Proteomics Bioinformatics
2025 May 10;23(1):qzaf008. PMID: 39957240 -
Commun Biol
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. [Abstract]2021 Jan 20;4(1):93. PMID: 33473151 -
J Gastroenterol
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]2019 May;54(5):449-458. PMID: 30684016 -
Antiviral Res
2026 Jun 22:252:106470. PMID: 42331291 -
J Hum Genet
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. [Abstract]2020 Jan;65(2):143-153. PMID: 31645655
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. [Content Brief]
[2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Beclabuvir hydrochloride Related Classifications
HY-12429A Related Classifications
Powered by Bioz